AbbVie Inc, which last week announced plans to purchase Dublin-based drugmaker Shire Plc for $55 billion, reported stronger-than-expected quarterly results on surging sales of its Humira treatment for rheumatoid arthritis.The U.S. drugmaker said on Friday that it had earned $1.1 billion, or 68 cents per share, in the second quarter. That compared with $1.07 billion, or 66 cents per share, a year earlier, when it took charges for research, separation costs and a restructuring.Excluding special items, AbbVie earned 82 cents per share. Analysts on average expected 76 cents, according to Thomson Reuters I/B/E/S.Sales rose 5 percent to $4.93 billion, topping Wall Street expectations of $4.7 billion. AbbVie attributed the growth mainly to Humira, an injectable treatment whose global sales jumped 26 percent to $3.29 billion.
AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. Shares of ABBV remained unchanged at $54.08. In the past year, the shares have traded as low as $42.25 and as high as $58.27. On average, 7980000 shares of ABBV exchange hands on a given day and today's volume is recorded at 31808.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI remained unchanged at $37.01. In the past year, the shares have traded as low as $32.87 and as high as $38.73. On average, 767910 shares of TRI exchange hands on a given day and today's volume is recorded at 0.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 0.35% or $0.14/share to $39.76. In the past year, the shares have traded as low as $34.52 and as high as $42.10. On average, 584056 shares of TRI.TO exchange hands on a given day and today's volume is recorded at 381245.
Source
